RASP (Actavia Life Sciences) Short-Term Debt: $0.30 Mil (As of Mar. 2024)


What is Actavia Life Sciences Short-Term Debt?

Actavia Life Sciences RASP -87.50% Short-Term Debt is $0.30 Mil as of Mar. 2024.

Actavia Life Sciences's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.30 Mil.

Actavia Life Sciences's quarterly Short-Term Debt increased from Sep. 2023 ($0.21 Mil) to Dec. 2023 ($0.23 Mil) and increased from Dec. 2023 ($0.23 Mil) to Mar. 2024 ($0.30 Mil).

Actavia Life Sciences's annual Short-Term Debt declined from Sep. 2021 ($0.68 Mil) to Sep. 2022 ($0.13 Mil) but then increased from Sep. 2022 ($0.13 Mil) to Sep. 2023 ($0.21 Mil).

Actavia Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Actavia Life Sciences Short-Term Debt Related Terms

Actavia Life Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Short-Term Debt Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.52 0.68 0.13 0.21

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.22 0.21 0.23 0.30
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.30 Mil mean?
Actavia Life Sciences (RASP) has a Short-Term Debt of $0.30 Mil as of Mar. 2024.
Is Actavia Life Sciences' Short-Term Debt too high?
Actavia Life Sciences' current Short-Term Debt is $0.30 Mil.
How does Actavia Life Sciences' Short-Term Debt compare to BWV and FNCH?
Actavia Life Sciences' Short-Term Debt of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Actavia Life Sciences's current Short-Term Debt is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Short-Term Debt of $0.30 Mil. The current Short-Term Debt is $0.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Short-Term Debt is $0.30 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.